08Nov/13

OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) – Opportunity … – PR Carbon (press release)

OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) – Opportunity
PR Carbon (press release)
FOR IMMEDIATE RELEASE, Illinois – United States – November 8, 2013 (PR Carbon):Reportstack has announced a new market report on OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) – Opportunity Analysis and Forecasts to 2017.

08Nov/13

Pfizer Inc. : Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of … – 4-traders (press release)


Drug Discovery & Development

Pfizer Inc. : Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of
4-traders (press release)
Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE® 3 to 5 months after transplant. The primary
Pfizer Inc. (NYSE:PFE) | Pfizer Announces Top-Line Results Of Phase 3B/4 Jutia Group
Pfizer says organ transplant drug fails in studyBusinessweek
Pfizer’s Rapamune Doesn’t Meet Primary Endpoint in Study of Kidney Transplant Wall Street Journal

all 4 news articles »